Xenon Pharmaceuticals Inc. (XENE) Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Xenon Pharmaceuticals Inc. NASDAQ:XENE Healthcare · Biotechnology
Mkt Cap $3.62B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals announced inducement equity grants to nine new non-officer employees totaling 24,250 share options and 14,250 RSUs, effective October 29, 2026.
The options carry a $37.54 exercise price equal to the grant-date close and vest over four years under the company's 2025 Inducement Equity Incentive Plan.
This is a routine Nasdaq Listing Rule 5635(c)(4) compliance disclosure with no material financial or strategic impact.
• 2d ago AI analysis › Press Release ⚠ 2
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
Xenon reported positive Phase 1 data for XEN1701 and XEN1120, supporting advancement of both non-opioid pain candidates into Phase 2 proof-of-concept acute pain studies expected to begin in H1 2027.
XEN1701 achieved more than 75% Na(V)1.7 receptor occupancy in both peripheral and central nervous system with twice-daily dosing and showed no consistent pattern of cardiovascular effects, a common failure point for prior Na(V)1.7 programs.
Preclinical data in cynomolgus monkeys showed approximately 85-100% reductions in capsaicin-evoked heat pain at comparable exposure levels without effects on blood pressure or heart rate; XEN1120 also showed opioid-like activity in the acute phase of the mouse formalin model.
Both Phase 1 studies were generally well-tolerated with no dose-limiting or serious treatment-emergent adverse events.
• 3d ago AI analysis › Press Release ⚠ 1
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP is continuing an investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals (XENE) common stock.
The release recaps that Xenon paused new patient enrollment in its MDD and bipolar depression studies on September 17, 2026, after which the stock fell 30.7% to $39.75.
This is a law-firm solicitation, not a company disclosure; no claims have been filed and there is no new substantive development.
• 12d ago AI analysis › Press Release ⚠ 1
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals (NASDAQ: XENE) common stock.
The investigation follows Xenon's September 17, 2026 disclosure of a voluntary pause in new patient enrollment in its MDD and bipolar depression studies after an analysis of neuropsychiatric adverse events; the stock fell 30.7% to $39.75 on September 18.
This release is a law-firm solicitation encouraging investors to contact counsel — it is not a new company disclosure and adds no new clinical or financial information.
• 25d ago AI analysis › Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals granted inducement equity awards to eight new non-officer employees under Nasdaq Listing Rule 5635(c)(4).
The grants total 17,850 share options with a $38.93 exercise price and 10,500 RSUs, all effective October 1, 2026 under the Amended and Restated 2025 Inducement Equity Incentive Plan.
Dilution is immaterial relative to shares outstanding; the release is administrative boilerplate with no pipeline or financial updates.
• 0mo ago AI analysis › Press Release
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Defence Therapeutics (CSE: DTC) appointed finance executive Sherry Aulin to its Board of Directors and Audit Committee.
Aulin spent over a decade as CFO of Xenon Pharmaceuticals (NASDAQ: XENE), where she helped lead its Nasdaq IPO and raised more than US$1 billion in equity capital.
She received 400,000 stock options at 40 cents per share, half vesting immediately, in connection with the appointment.
• 1mo ago AI analysis › Press Release ⚠ 1
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP announced an investigation into potential claims on behalf of Xenon Pharmaceuticals (XENE) investors; no new company disclosure.
The solicitation references Xenon's September 17, 2026 voluntary pause on enrollment in its MDD and bipolar depression Azetukalner studies following an analysis of neuropsychiatric adverse events.
Shares fell 30.7% to $39.75 on the news; this release is law-firm marketing, not issuer action, and should be treated as low-signal noise.
• 1mo ago AI analysis › Press Release
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Xenon Pharmaceuticals announced it will present at the TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit via a virtual fireside chat on Wednesday, September 23, from 2:00 to 2:25 pm ET.
Webcast details and replay access will be available through the Investors section of Xenon's website, with the listed dates and times subject to change.
This is routine investor-outreach scheduling with no new clinical or financial data; the release reiterates that lead molecule azetukalner is in late-stage development for epilepsy, major depressive disorder, and bipolar depression.
• 1mo ago AI analysis › Press Release ● Major ⚠ 3
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Xenon Pharmaceuticals has submitted a New Drug Application for azetukalner in focal seizures to the FDA, based on positive data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 studies in which all four doses showed statistically significant reductions in monthly seizure frequency versus placebo.
Separately, Xenon has voluntarily paused enrollment of new patients in its MDD and bipolar depression studies after an analysis of neuropsychiatric adverse events; already-enrolled participants remain on study, and the company says the events are consistent with azetukalner's known safety profile but had not been seen in the Phase 2 X-NOVA study.
The X-NOVA2 MDD study completed enrollment with approximately 360 patients — roughly 80% of the initial 450-patient target — and topline data are now expected in Q1 2027.
The Phase 3 epilepsy studies X-TOLE3 and X-ACKT continue enrolling, supported by more than 1,500 patient-years of safety data across the program; management framed the NDA as a significant milestone toward Xenon's first approval and launch as a fully integrated neuroscience company.
• 1mo ago AI analysis › Press Release
Xenon to Present at Wells Fargo Healthcare Conference
Xenon Pharmaceuticals announced it will present at the Wells Fargo Healthcare Conference in Boston, with a fireside chat scheduled for Wednesday, September 9, from 11:00 to 11:30 am ET.
The release contains no financial results, clinical data, or strategic updates; webcast details and replay availability are posted on Xenon's investor relations site, and dates are subject to change.
Xenon's lead molecule azetukalner remains in late-stage development for epilepsy, major depressive disorder, and bipolar depression, but this notice itself advances none of that pipeline story.
• 1mo ago AI analysis › Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals granted inducement equity awards to five new non-officer employees consisting of stock options and restricted share units.
The grants include an aggregate of 13,450 share options and 7,850 RSUs, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
Share options have an exercise price of $61.93 and vest over four years, while the RSUs vest annually over four years.
• 2mo ago AI analysis › Press Release
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
Xenon Pharmaceuticals announced it will present detailed Phase 3 X-TOLE2 data and long-term safety results for its lead asset azetukalner at the European Epilepsy Congress in Athens.
The presentations include mechanistic data supporting rational polytherapy and 48-month outcomes from the open-label extension study, highlighting the drug's potential additive effects with other antiseizure medications.
The X-TOLE2 study evaluated 374 patients with treatment-resistant focal onset seizures who had a median of five prior antiseizure medications.
• 2mo ago AI analysis › Press Release ⚠ 1
Xenon Reports Q2 2026 Financial Results and Provides Business Update
Xenon reported a Q2 net loss of $110.7 million, widening from $84.7 million in the prior year, driven by increased R&D spending on Phase 3 programs and manufacturing activities for its planned NDA submission.
The company's cash position more than doubled to $1.25 billion, providing a cash runway into 2029 to fund operations and support its late-stage pipeline.
Management reaffirmed that the NDA submission for lead asset azetukalner in focal onset seizures remains on track for the third quarter of 2026, with multiple Phase 3 studies in neuropsychiatry and pain continuing to enroll.
• 2mo ago AI analysis › Press Release
F4 Begins Search for Radioactive Boulders at Todd and Wales Lake
F4 Uranium announced the commencement of a high-resolution airborne radiometric survey over its Todd and Wales Lake projects to locate radioactive boulder trains.
The survey covers approximately 3,850 line kilometres and aims to identify vectors toward uranium mineralization similar to nearby discoveries by Paladin Energy and NexGen Energy.
Separately, F4 appointed Sonia Graham as CFO, noting her previous role in Xenon Pharmaceuticals' IPO; she replaces outgoing CFO Jeremy Polmear.
• 2mo ago AI analysis › Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals granted equity inducement awards to eleven new non-officer employees, consisting of an aggregate of 32,758 share options and 19,013 restricted share units.
The share options have an exercise price of $64.19 per share, matching the closing price on the grant date, and vest over four years with a one-year cliff.
The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the July 30, 2026 grant date, subject to continued employment.
• 3mo ago AI analysis › Press Release
Xenon to Report Q2 2026 Financial Results on August 6, 2026
Xenon Pharmaceuticals announced it will report its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update.
• 3mo ago AI analysis › Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals granted 20,200 share options and 11,850 restricted share units to four new non-officer employees as employment inducements.
The options have an exercise price of $60.30, equal to the closing price on the grant date, and vest over four years with a one-year cliff.
The RSUs vest 25% annually over four years, and all grants were approved under the Amended and Restated 2025 Inducement Equity Incentive Plan.
• 4mo ago AI analysis › Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals disclosed equity inducement grants to 10 new non-officer employees.
The grants consist of 32,750 share options and 19,200 restricted share units (RSUs), approved by the Compensation Committee.
Options were priced at $54.79, matching the May 28 closing price, and vest over four years subject to continued service.
• 5mo ago AI analysis › Press Release ● Major ⚠ 2
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals reported Q1 2026 financial results highlighted by a cash position of $1.3 billion, which extends the company’s runway into 2029 following significant capital raises during the quarter.
The company confirmed it anticipates submitting a New Drug Application for its lead asset azetukalner in Q3 2026, following positive Phase 3 X-TOLE2 data for focal onset seizures announced in March.
Research and development expenses increased to $88.5 million, driving a net loss of $102.3 million for the quarter, as multiple Phase 3 studies in epilepsy and depression continue to enroll.
• 5mo ago AI analysis › Press Release
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon granted inducement awards to seven new non-officer employees, totaling 25,600 options and 15,000 RSUs approved by the Compensation Committee on April 30.
The options were granted at the money with an exercise price of $56.04, equal to the closing price on the grant date.
Vesting schedules are standard, with options vesting over four years and RSUs vesting 25% annually for four years.
• 6mo ago AI analysis › Press Release
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals announced it will report its first quarter 2026 financial results and provide a business update after the market close on Thursday, May 7, 2026.
The company will host a conference call and webcast at 4:30pm ET to discuss the results, which will be available for replay on the Investors section of its website.
Xenon's lead molecule azetukalner is currently in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder, and bipolar depression.
• 6mo ago AI analysis › 
